Conclusion
We concluded that TSG's protective effect against OGD-induced in vitro ischemic cell model was associated to Akt/Caspase-3 pathway. TSG might be explored as a therapeutic target for ICM.
Methods
Rat cardiomyoblast cell line H9c2 was cultured in oxygen-glucose withdrawal medium for 8 hours to establish an in vitro cell model of oxygen-glucose deprivation (OGD). Cells were pretreated with TSG to test the protective effect of it against OGD. Cell viability, apoptosis, mitochondrial transmembrane potential (ΔΨm), and apoptosis related proteins were detected using appropriated methods. Differences between treatments were analyzed.
Objective
This study was designed to investigate the effect of TSG (2, 3, 5, 4'-tetrahydroxystibene-2-O-β-D-glucoside) on ischemic cardiomyopathy (ICM) related cell apoptosis and the mechanism related to it in vitro.
Results
OGD treatment inhibited cell viability, expression of Akt and Bax, induced loss of ΔΨm, cell apoptosis, and triggered expression of Bcl-2 and Caspase-3/9. TSG pretreatment, on the contrary, suppressed OGD-induced cell apoptosis, ΔΨm loss, Bcl-2 and Caspase-3/9 expression, and promoted OGD-inhibited cell viability, Bax and Akt expression.